Literature DB >> 8882632

Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats.

Y Nishimura1.   

Abstract

1. The 5-hydroxytryptamine (5-HT) induced-contraction in ring preparations of basilar arteries from Wistar-Kyoto rats (WKY) and stroke-prone spontaneously hypertensive rats (SHRSP) was pharmacologically characterized in vitro. 2. Contractile responses to 5-HT (1 nM-100 nM) and their pD2 values in arteries from SHRSP at 6 months of age were significantly greater than those in age-matched WKY, although the maximum response did not differ between the two groups. 3. There were no significant differences in contractile responses to U-44619, endothelin-1, neuropeptide Y, and angiotensin II between WKY and SHRSP arteries. 4. Spiperone (1 nM-1 microM, a 5-HT2 receptor antagonist), produced biphasic displacement of the 5-HT curves in WKY and SHRSP arteries. The response to high concentrations of 5-HT was concentration-dependently antagonized by spiperone, while the response to low concentrations of 5-HT was resistant to blockade by spiperone, and the spiperone-resistant contractile responses induced by 5-HT were greater in SHRSP than in WKY. Ketanserin (1-100 nM, 5-HT2) also produced a biphasic shift of the 5-HT curves for both arteries. 5. Methiothepin (10 and 100 nM, 5-HT1 and 5-HT2) potently inhibited 5-HT-induced contractions in both groups. In addition, methiothepin (100 nM) produced a parallel shift to the right of the component of 5-HT-induced contractile responses that was resistant to blockade by spiperone in both groups. 6. The contractile effects of 5-HT in WKY and SHRSP arteries were not affected by MDL 72222 (1 microM, 5-HT3) and SDZ 205-557 (1 microM, 5-HT4). In addition, cocaine (10 microM), pargyline (50 microM), prazosin (10 microM), indomethacin (3 microM) and SQ 29,548 (1 microM) did not affect the contractile effects of 5-HT in either artery. 7. Contractile responses to 5-carboxamidotryptamine, CGS 12066B, pindolol and propranolol were greater in SHRSP arteries than in WKY arteries, whereas contractions in response to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), alpha-methyl-5-HT and 2-methyl-5-HT did not differ between the two groups. Cisapride failed to contract basilar arteries in both groups. Furthermore, a correlation analysis showed a highly significant correlation between the pD2 values of 5-HT agonists in WKY and SHRSP arteries and their published binding affinities at the 5-HT1B subtype. 8. These findings suggest that 5-HT elicits vasoconstriction in rat basilar arteries by stimulation of a mixed receptor population of 5-HT2 and 5-HT1-like receptors (similar to the 5-HT1B receptor subtype), and that the contraction mediated by 5-HT1-like receptors is enhanced in the basilar artery from SHRSP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882632      PMCID: PMC1909781          DOI: 10.1111/j.1476-5381.1996.tb16732.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Contractile 5-HT1 receptors in human isolated pial arterioles: correlation with 5-HT1D binding sites.

Authors:  E Hamel; D Bouchard
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

Review 2.  5-HT receptors: subtypes and second messengers.

Authors:  D Hoyer; P Schoeffter
Journal:  J Recept Res       Date:  1991

3.  5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some beta-adrenoceptor antagonists.

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

4.  Evidence for the presence of 5-HT1-like receptors in rabbit isolated basilar arteries.

Authors:  A A Parsons; E T Whalley
Journal:  Eur J Pharmacol       Date:  1989-12-19       Impact factor: 4.432

5.  Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system.

Authors:  N Adham; B Ellerbrock; P Hartig; R L Weinshank; T Branchek
Journal:  Mol Pharmacol       Date:  1993-03       Impact factor: 4.436

6.  Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.

Authors:  E Hamel; E Fan; D Linville; V Ting; J G Villemure; L S Chia
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

7.  Heterogeneity of 5-HT receptor subtypes in isolated human femoral and saphenous veins.

Authors:  E Glusa; E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

8.  5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences.

Authors:  I Jansen; J Olesen; L Edvinsson
Journal:  Acta Physiol Scand       Date:  1993-02

Review 9.  Cerebral vascular changes during chronic hypertension: good guys and bad guys.

Authors:  D D Heistad; G L Baumbach
Journal:  J Hypertens Suppl       Date:  1992-12

10.  Mechanism of pindolol-induced vasoconstriction in isolated and perfused dog coronary arteries.

Authors:  T Nakane; K Kawai; S Chiba
Journal:  Jpn J Pharmacol       Date:  1993-05
View more
  9 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Mitochondrial monoamine oxidase-A-mediated hydrogen peroxide generation enhances 5-hydroxytryptamine-induced contraction of rat basilar artery.

Authors:  Christina Chui Wa Poon; Sai Wang Seto; Alice Lai Shan Au; Qian Zhang; Rachel Wai Sum Li; Wayne Yuk Wai Lee; George Pak Heng Leung; Siu Kai Kong; John Hok Keung Yeung; Sai Ming Ngai; Ho Pui Ho; Simon Ming Yuen Lee; Shun Wan Chan; Yiu Wa Kwan
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

4.  Rho-kinase and the nitric oxide pathway modulate basilar arterial reactivity to acetylcholine and angiotensin II in streptozotocin-induced diabetic mice.

Authors:  Md Zahorul Islam; Cuong Van Dao; Atsushi Miyamoto; Mitsuya Shiraishi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-27       Impact factor: 3.000

5.  Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery.

Authors:  Bharath K Mani; Lioubov I Brueggemann; Leanne L Cribbs; Kenneth L Byron
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  Inhibition of cerebral vasoconstriction by dantrolene and nimodipine.

Authors:  Salvatore Salomone; Guray Soydan; Michael A Moskowitz; John Randall Sims
Journal:  Neurocrit Care       Date:  2008-10-16       Impact factor: 3.210

7.  Elevated K+ channel activity opposes vasoconstrictor response to serotonin in cerebral arteries of the Fawn Hooded Hypertensive rat.

Authors:  Mallikarjuna R Pabbidi; Richard J Roman
Journal:  Physiol Genomics       Date:  2016-10-27       Impact factor: 3.107

8.  Trigeminovascular effects of propranolol in men and women, role for sex steroids.

Authors:  Eloísa Rubio-Beltrán; Rianne M Schoon; Jeffrey van den Berg; Catharina C M Schuiling-Veninga; Birgit C P Koch; Carlos M Villalón; Jorie Versmissen; A H Jan Danser; Anton H van den Meiracker; Khatera Ibrahimi; Antoinette MaassenVanDenBrink
Journal:  Ann Clin Transl Neurol       Date:  2022-08-27       Impact factor: 5.430

9.  Involvement of organic cation transporter-3 and plasma membrane monoamine transporter in serotonin uptake in human brain vascular smooth muscle cells.

Authors:  Rachel W S Li; Cui Yang; Y W Kwan; S W Chan; Simon M Y Lee; George P H Leung
Journal:  Front Pharmacol       Date:  2013-02-12       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.